The purpose of this study is to compare Zoladex plus tamoxifen with tamoxifen alone as
adjuvant hormonal therapy in pre- or perimenopausal women with early-stage breast cancer in
terms of breast density, estrogen levels, lipidemia, endometrial thickness and
ultrasonographic abnormalities.